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ABSTRACT
Tumor hypoxia has been attracting increasing attention in the ﬁelds of radiation biology and oncology since
Thomlinson and Gray detected hypoxic cells in malignant solid tumors and showed that they exert a negative
impact on the outcome of radiation therapy. This unfavorable inﬂuence has, at least partly, been attributed to
cancer cells acquiring a radioresistant phenotype through the activation of the transcription factor, hypoxia-
inducible factor 1 (HIF-1). On the other hand, accumulating evidence has recently revealed that, even though HIF-1
is recognized as an important regulator of cellular adaptive responses to hypoxia, it may not become active and induce
tumor radioresistance under hypoxic conditions only. The mechanisms by which HIF-1 is activated in cancer cells
not only under hypoxic conditions, but also under normoxic conditions, through cancer-speciﬁc genetic alterations
and the resultant imbalance in intermediate metabolites have been summarized herein. The relevance of the HIF-1–
mediated characteristic features of cancer cells, such as the production of antioxidants through reprogramming of the
glucose metabolic pathway and cell cycle regulation, for tumor radioresistance has also been reviewed.
KEYWORDS: hypoxia-inducible factor 1 (HIF-1), radioresistance, cancer, metabolic reprogramming, tumor blood
vessels, cell cycle, Warburg effect
INTRODUCTION
High-precision radiation therapy enables radiation oncologists to
decrease delivery of an excessive dose of radiation to normal tissues
and also to administer a high and booster dose of radiation, particu-
larly to small target fractions in a malignant tumor [1]. In order to
efﬁciently use this technique in the future for cancer patients, a better
understanding of the characteristics of radioresistant cancer cells in
malignant solid tumors is needed. Based on accumulating evidence,
molecular oxygen is recognized as one of the most inﬂuential factors
on the cytotoxic effects of radiation; in other words, cancer cells may
be radioresistant under hypoxic conditions in solid tumors [2–4].
This has been attributed to the reactivity of molecular oxygen, e.g.
oxygen has high afﬁnity for free radicals produced by radiation in cel-
lular components such as DNA and maintains them in unrepairable
forms [2, 3]. In addition to this chemical mechanism of radiation,
cellular adaptive responses to hypoxia mediated by the hypoxia-
inducible transcription factor, HIF-1, have been suggested to function
in the induction of biological radioresistance in cancer cells under
hypoxic conditions; therefore, HIF-1 has been attracting increasing
attention in the ﬁeld of radiation oncology [3–7].
On the other hand, biochemistry and molecular biology–based re-
search on the molecular mechanisms underlying the activation of HIF-1
have revealed that the deprivation of oxygen is not necessarily important
[8, 9]. For example, some genetic alterations have been shown to lead
to the activation of HIF-1, even in the presence of oxygen, through
decreases in the levels of either Fe2+ or an intermediate metabolite of
the tricarboxylic acid cycle (TCA cycle), α-ketoglutarate [8, 9]. Since
HIF-1 is strongly associated with the radioresistant phenotypes of
cancer cells, conditions that potentially lead to the activation of HIF-1
are now recognized as playing crucial roles in tumor radioresistance.
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The molecular mechanisms responsible for the activation of
HIF-1 have been described herein, and the functions of HIF-1 in the
induction of tumor radioresistance and tumor recurrence after radi-
ation therapy have been reviewed.
MECHANISMS UNDERLYING THE ACTIVATION
OF HIF-1
Activation of HIF-1 under hypoxic conditions
HIF-1, which was originally identiﬁed as a transcription factor for the
expression of the erythropoietin (EPO) gene under hypoxic condi-
tions [10–12], is composed of alpha and beta subunits, HIF-1α and
HIF-1β, respectively (Fig. 1). In contrast to the constitutive expres-
sion of HIF-1β, the expression levels and transactivation activity of
HIF-1α are downregulated in an oxygen-dependent manner, which is
mainly responsible for the hypoxia-dependent activation of the het-
erodimer, HIF-1 [13]. More speciﬁcally, the HIF-1α protein is hydro-
xylated on two proline residues (P402 and P564) and one asparagine
(N803) residue by two kinds of dioxygenases, prolyl hydroxylases
(prolyl-4-hydroxylases: PHDs) and asparaginyl hydroxylase (factor-
inhibiting HIF-1: FIH-1), respectively [13]. These dioxygenases
require molecular oxygen for their activity and, thus, do not function
under oxygen-deprived conditions [13]. Oxygen-dependent and PHDs-
mediated prolyl hydroxylation lead to the ubiquitination of HIF-1α by
von Hippel Lindau (VHL)-containing E3 ubiquitin ligase and subse-
quent proteolysis by the 26S proteasome, which is responsible for the
oxygen-dependent degradation of the HIF-1α protein [13–18].
Oxygen-dependent and FIH-1–mediated asparaginyl hydroxylation
suppress the recruitment of the transcriptional co-activators, p300/
CREB-binding protein (CBP) acetyltransferases, to the HIF-1α protein,
resulting in the oxygen-dependent blocking of the transactivation activ-
ity of the HIF-1α protein [13, 19]. In contrast, the HIF-1α protein
becomes stable and acquires transactivation activity under hypoxic
conditions because of the inactivation of these oxygen-dependent
dioxygenases [13]. HIF-1α then interacts with its binding partner
HIF-1β, and the resultant heterodimer, HIF-1, begins to induce the
transcription of no less than 800 genes that function in adapting to
hypoxic environments (e.g. metabolic reprogramming [20–23]),
escaping hypoxic conditions (invasion and metastasis of cancer cells
[24–26]), and improving oxygen availability (angiogenesis and neovas-
cularization [7, 23, 25]).
Hypoxia-independent activation of HIF-1
In recent years, studies have demonstrated that HIF-1 becomes active
even in the presence of oxygen when the following conditions are
satisﬁed.
Decrease in activity of dioxygenases
Since the hydroxylation activity of dioxygenases is dependent not
only on oxygen, but also on Fe2+ and α-ketoglutarate, HIF-1
becomes active when the levels of either of these decreases in cells,
even in the presence of oxygen [27, 28]. A dysfunction in the TCA
cycle has been associated with reductions in α-ketoglutarate levels
and the resultant activation of HIF-1. For example, Selak et al.
reported that a deﬁciency in succinate dehydrogenase (SDH), which
is often conﬁrmed in some types of cancers, results in the accumula-
tion of succinate in cells [29]. Since succinate potentially inhibits the
decarboxylation of α-ketoglutarate to succinate and increases the
intracellular levels of α-ketoglutarate, a SDH deﬁciency in cancer
cells inhibits both prolyl and asparaginyl hydroxylases, thereby upre-
gulating the stability and transactivation activity of HIF-1α [29].
Zeng et al., from my laboratory, showed the importance of abnormal-
ities in the expression of another TCA cycle enzyme in the reduction
of α-ketoglutarate levels [23]. We found that the aberrant expression
of the wild-type isocitrate dehydrogenase 3α gene (IDH3α) reduced
α-ketoglutarate levels and increased the stability and transactivation
activity of HIF-1α by facilitating the reductive carboxylation of
α-ketoglutarate to isocitrate in transformed cells [23]. In addition to
decreased α-ketoglutarate levels, Isaacs et al. revealed that fumarate,
the levels of which are elevated as a result of a fumarate hydroxylase
deﬁciency in cancer cells, also increases the expression levels of HIF-
1α through inhibition of the activity of PDHs by directly competing
with its co-factor, α-ketoglutarate [30].
Factors that potentially decrease intracellular Fe2+ levels are also
inﬂuential in the activation of HIF-1 activity under normoxic condi-
tions because Fe2+ is an essential co-factor for PHDs and FIH-1 as
described above [27, 28]. One example is the inﬂuence of reactive
oxygen species (ROS). ROS have been shown to play pivotal roles as
messengers in signal transduction and cell cycle regulation [31]. Since
one of the main sources of ROS is mitochondria, dysfunctional mito-
chondria in cancer cells produce excessive amounts of ROS, leading to
decreases in Fe2+ levels through its oxidation to Fe3+. Thus, the aber-
rant accumulation of ROS induces HIF-1 activity by inactivating dioxy-
genases [28]. Although ionizing radiation also induces the production
of ROS and HIF-1 activity, its details will be described in a later section
on tumor radioresistance (see Section 4.1).
Impairments in E3 ubiquitin ligase and deubiquitination
After the hydroxylation of P402 and P564 in HIF-1α, VHL-
containing E3 ubiquitin ligase recognizes the HIF-1α protein for
ubiquitination, leading to the proteolysis of HIF-1α through the ubi-
quitin–proteasome system [13–18]. Therefore, a VHL deﬁciency is
also considered to cause the accumulation of the HIF-1α protein,
even in the presence of oxygen [27]. Park et al. highlighted the
importance of mutations in another E3 ligase component, Cullin 2
(CUL2) [32]. They identiﬁed CUL2 frameshift mutations in colon
cancers and suggested that mutations inactivate the tumor suppressor
function of CUL2 through HIF-1α proteolysis [32].
Goto et al., from my lab, recently demonstrated the critical role of
a deubiquitinating enzyme in the stabilization of HIF-1α [24]. In a
genetic screening experiment, we identiﬁed ubiquitin C-terminal hydro-
lase L1 (UCHL1) as a novel deubiquitinating enzyme for the HIF-1α
protein [24]. The aberrant overexpression of UCHL1 stabilized the
HIF-1α protein and induced HIF-1 activity under normoxic and
hypoxic conditions [24].
Increases in transcription and translation initiation of HIF-1α
In addition to post-translational mechanisms, regulation at the level
of transcription and translation initiation is also important for the
activation of HIF-1 under normoxic conditions (Fig. 1). Koshikawa
et al. reported that ROS generated in mitochondria upregulated the
transcription of the HIF-1α gene via the phosphatidylinositol 3
kinase-Akt/protein kinase C/histone deacetylase (PI3K-Akt/PKC/
HDAC) pathway, leading to the accumulation and activation of
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HIF-1α in tumor cells [33]. Regarding translational initiation of the
HIF-1α gene, Laughner et al. demonstrated the importance of signal
transduction cascades [34]. Their in vitro study revealed that HER2
signaling did not affect the half-life of the HIF-1α protein, but stimu-




Recent advances in molecular biological research in the ﬁelds of
radiation oncology and biology have led to the potential of HIF-1 in
enhancing the radioresistance of cancer cells being recognized [5, 7,
35]. The functions of HIF-1 in the induction of tumor radioresistance
through the reprogramming of glucose metabolism and cell cycle
regulation have been summarized.
Reprogramming of glucose metabolism and resultant
overproduction of antioxidants
The growth advantage of cancer cells has been attributed to unique
glucose metabolic pathways that produce ATP through accelerated
glycolysis rather than mitochondrial oxidative phosphorylation under
normoxic as well as hypoxic conditions. This is known as the
Warburg Effect (Fig. 2) [36, 37]. The transcription factor, HIF-1,
plays fundamental roles in the reprogramming as followings [9, 22,
36–38]. HIF-1 accelerates glycolysis by inducing the expression of
glycolytic enzymes, except for phosphoglyceric acidmutase (PGAM),
at the transcription level [22, 39]. Moreover, HIF-1 inhibits the con-
version of pyruvate to a substrate of the TCA cycle, acetyl-CoA, by
inducing the expression of pyruvate dehydrogenase kinase 1 (PDK1)
[40]. Furthermore, HIF-1 induces mitochondrial autophagy, mito-
phagy, by upregulating the expression of BCL2/adenovirus E1B
19 kDa interacting protein 3 (BNIP3) in order to directly reduce the
mitochondrial mass [21, 41]. The HIF-1-mediated metabolic repro-
gramming, especially increased expression of glycolytic enzymes, e.g.
glucose transporter-1 (GLUT1) and hexokinase 2 (HK2), leads to
the increase in intracellular levels of glucose and glucose-6-phosphate.
Since glucose-6-phosphate serves as a substrate for the pentose phos-
phate pathway (PPP) responsible for the biogenesis of the antioxi-
dants NADPH and glutathione [42], the HIF-1–mediated Warburg
effect has been associated with the induction of antioxidant capacity
and eventual radioresistance of cancer cells (Fig. 2) [43]. We actually
conﬁrmed that accelerated glycolysis mediated by aberrant overex-
pression of IDH3α, and the resultant upregulation of HIF-1 activity
led to the radioresistance of cancer cells. However, the molecular
mechanism underlying the relationship between the HIF-1–mediated
metabolic reprogramming and PPP has not necessarily been eluci-
dated yet. For example, although functional and mechanistic links
between HIF-1 and p53 have been reported so far, it remains unclear
whether they function in balancing the metabolic reprogramming and
the PPP. In addition, whereas it has been reported that p53 poten-
tially suppresses the PPP by inactivating a rate-limiting enzyme of
PPP, glucose-6-phosphate dehydrogenase (G6PD) [44], p53 was
also demonstrated to induce the expression of TP53-induced
Fig. 1. Molecular mechanisms underlying the activation of HIF-1.
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glycolysis and apoptosis regulator (TIGAR), which promotes the
PPP through the activation of G6PD and functions in the mainten-
ance of redox homeostasis and radioresistance of cells [42, 43]. A
hint to accessing these missing links may be in the line of a recent
report that TIGAR activates HK2 through their direct interaction
under hypoxic conditions in a HIF-1–dependent manner [45]. Also,
as suggested by Stanton, the balance of G6PD stimulatory versus
G6PD inhibitory signals downstream of p53 may be important in the
redox homeostasis and resultant radioresistance of cancer cells [46].
Cell cycle regulation
The Bergonie–Tribondeau’s law in the ﬁeld of radiation oncology
and biology indicates that cells are generally more sensitive to radi-
ation when they exhibit a marked increase in proliferative capacity
[47, 48]. Therefore, HIF-1–mediated cell cycle arrest or retardation
has been suggested to play a role in enhancing the radioresistance of
cancer cells. Several independent studies recently demonstrated that
cell cycle progression was blocked at G1/S transition under hypoxic
conditions. Koshiji et al. showed that hypoxia induced G1 cell cycle
arrest by upregulating the expression of CDNK1A, which encodes
the CDK2 inhibitor p21Cip1, through the displacement of Myc from
the CDNK1A promoter via HIF-1α [49]. Hammer et al., from the
same group, also demonstrated that hypoxia inhibited the expression
of CDC25A, another cell cycle regulator encoding a tyrosine phos-
phatase that maintains CDK2 activity, resulting in cell cycle arrest at
the G1 checkpoint [50]. Although cells are more radiosensitive at the
late G1 and early S phases than at the late S phase, cell cycle arrest/
retardation at any checkpoint is considered to enhance the radioresis-
tance of cancer cells, based on the Bergonie–Tribondeau’s law.
HIF-1-MEDIATED PROMOTION OF TUMOR
RECURRENCE AFTER RADIATION THERAPY
In addition to the function of HIF-1 in the induction of the radiore-
sistant characteristics of cancer cells, other mechanisms, by which
tumor recurrence after radiation therapy is promoted as a result of
the activation of HIF-1, have recently been proposed.
Fig. 2. HIF-1–mediated reprogramming of the glucose metabolic pathway from the mitochondrial oxidative phosphorylation to
glycolysis, which is the so-called ‘Warburg effect’. The reprogramming coupled with the activation of the pentose phosphate
pathway (PPP) induces radioresistance of cancer cells.
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Protection of tumor blood vessels
Radiation therapy exerts cytotoxic effects not only on cancer cells, but
also on the tumor vasculature in its treatment ﬁeld. Previous stud-
ies suggested the existence of a phenomenon in which cancer cells
protect the tumor vasculature from the cytotoxic effects of radiation
in a HIF-1–dependent manner, as follows (Fig. 3) [5, 51, 52]. Radi-
ation efﬁciently kills cancer cells in normoxic regions, resulting in the
so-called reoxygenation of hypoxic tumor cells [51, 53, 54]. HIF-1
becomes active in reoxygenated regions through the following mech-
anisms. We reported that the mTOR pathway promotes the synthesis
of the HIF-1α protein in glucose- and reoxygenation-dependent
manners in irradiated tumors [53]. Moeller et al. demonstrated that
reoxygenation stabilized the HIF-1α protein and enhanced the trans-
lational initiation of HIF-1 targets by increasing ROS levels and stress
granule depolymerization, respectively [51]. As a result, activated
HIF-1 increases the radioresistance of the tumor vasculature by
increasing the amount of the secreted proangiogenic cytokine, VEGF
[5, 51, 52, 55]. The involvement of HIF-1 and VEGF has been con-
ﬁrmed in in vivo studies; the HIF-1 inhibitor, YC-1, or a neutralizing
antibody against VEGF markedly induced apoptosis in endothelial
cells and decreased microvessel density after radiation therapy,
resulting in radiosensitizing effects in a tumor growth delay assay [51,
52, 54]. Collectively, these ﬁndings have provided a rational basis for
the combination of radiation and anti-angiogenic therapy in order to
enhance the therapeutic effects of radiation.
Repopulation of radio-surviving cancer cells
Lineage tracking of hypoxic tumor cells in vivo revealed the import-
ance of HIF-1 in tumor recurrence after radiation therapy [6]. We
constructed a very unique plasmid that expressed Cre recombinase fused
to an estrogen receptor (ERT2) under the control of a HIF-1-dependent
5HRE promoter, and established a system to tag HIF-1–positive
hypoxic tumor cells with luciferase proteins in a tumor xenograft [6].
The resultant lineage tracking revealed that, after surviving radiation
therapy, hypoxic tumor cells induced epithelial–mesenchymal
transition (EMT) in a HIF-1–dependent manner, translocated
toward tumor blood vessels, and eventually caused tumor recur-
rence after radiation therapy (Fig. 3). The incidence of tumor
recurrence was signiﬁcantly suppressed in tumor-bearing mice
treated with the HIF-1 inhibitor, YC-1, and by inhibiting EMT,
suggesting a critical role of HIF-1 in tumor repopulation after radi-
ation therapy [6].
Fig. 3. Dynamics of cancer cells after radiation therapy. Hypoxic tumor cells predominantly survive radiation therapy and protect
blood vessels by secreting VEGF in a HIF-1–dependent manner. The radiosurviving ex-hypoxic cancer cells translocate toward
the blood vessels and cause tumor recurrence and distant tumor metastases after radiation therapy [6].
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PERSPECTIVES
Accumulating evidence for how HIF-1 becomes active under not
only hypoxic conditions but also under normoxic conditions and also
for how HIF-1 functions in the induction of radioresistant characteris-
tics in cancer cells and tumor recurrence after radiation therapy have
been summarized.
Mathieu et al. showed that hypoxia, through the activation of
HIFs, induces a hESC-like transcriptional program, including the
induced pluripotent stem cell (iPSC) inducers, OCT4, NANOG,
SOX2, KLF4, cMYC and microRNA-302 in various cancer cell lines
[56]. In addition, it has been suggested that HIF-1 functions in
glucose metabolic reprogramming and the cell cycle arrest at the
G0/G1 phase of cancer stem cell–like cells (CSCs) [57]. Moreover,
since CSCs have been suggested to exhibit radioresistance through
the activation of DNA repair pathways [58], all these ﬁndings collect-
ively indicate that HIFs would function in the generation and main-
tenance of CSCs and are involved in the radioresistance of CSCs.
HIF-1 is now recognized as an excellent molecular target to
enhance the therapeutic effects of radiation because of its fundamen-
tal roles in tumor radioresistance and post-irradiation tumor recur-
rence [3–6, 25, 59–61]. However, when attempting to inhibit HIF-1
activity during radiation therapy, it is necessary to consider the timing
of combinations because the treatment regimen has been demonstrated
to determine whether a HIF-1 inhibitor enhances or inhibits the
therapeutic effects of radiation [54]. Our group previously demon-
strated that, following a treatment with YC-1 and then radiation, YC-1-
mediated increases in tumor hypoxia suppressed the effects of radiation
therapy. On the other hand, in a treatment in the reverse order, YC-1
suppressed the post-irradiation upregulation of HIF-1 activity and con-
sequently delayed tumor growth [53, 54]. Based on the combination of
HIF-1 blockade with conventional fractionated radiation therapy for
cancer patients, the optimization of treatment regimens by performing
basic research is needed in order to obtain better therapeutic beneﬁts.
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